Plenary Lectures
Judy McArthur Clark, Pfi zer, USA
“Alternative research and practice supported by international veterinary professionals such as IACLAM”
Julia Fentem, Unilever, UK
“Exploring new approaches to assess safety without animal testing” Paul Flecknell, Newcastle Univ., UK “Assessment and alleviation of pain and distress of laboratory animals”
Makoto Hayashi, NIHS, Japan
“3Rs in Mutation Research--from in vivo to in silico evaluation”
Special Lecture
Alan Goldberg, Johns Hopkins Univ., USA
“Alternative research for a quarter of the century”
Next President Special Lecture
Herman Koëter, EFSA, Italy
“Globalization of animal welfare concepts integrated in the scientific agenda of international agencies for regulatory risk assessment”
Animal Welfare Memorial Lecture
Michael Balls, FRAME, UK
“Professor William Russell (1925-2006): Doyen of the Three Rs”
Themes, Organizers and Sessions
Theme 1: Animal Welfare
Organizers
Timothy H. Morris, GSK, UK
Marty Stephens, Humane Soc., USA
Takashi Agui, JALAM, Hokkaido Univ., Japan
Tsutomu.M. Kurosawa, Osaka Univ., Japan
1-1 Animal care
1-2 Prevention of pain and distress
1-3 Laboratory animal medicine
1-4 Transportation
1-5 Endpoints
1-6 in vivo experiments for refi nement
1-7 Replacement of primates
Theme 2: Moral, Ethical and Cultural Issues, and Public Policies of Animal Usage
Organizers
Clement Gautier, CCAC, Canada
Franz P. Gruber, Zurich, Switzerland
Margaret Snyder, NIH, USA
Takuya Ikeda, JALAE, GSK K.K. Japan
Yasuo Ohno, NIHS, Japan
2-1 Genetically engineered animals and the 3Rs: moral responsibility in the generation of new animals
2-2 Ethics committees as an international platform for communication and action on the 3 Rs
2-3 Cultural progress in animal welfare and 3Rs principles in Asian countries
2-4 Public participation in decision-making on animal use in different cultural contexts
2-5 Impacts of policy implementation on trends in animal use in science
Theme 3: 3Rs in Education and Training
Organizers
Ann Turner, AALAS, USA
Jan van der Valk, Utrecht Univ., Netherlands
Kazuo Ohwada, JALAS, Nat. Inst. Adv. Ind. Sci. and Technol., Japan
Masaharu Akita, Kamakura Women's Univ. Japan
3-1 Meeting learning objectives with non-animal models
3-2 New alternatives in education: human or animal based
3-3 New methods for humane education
3-4 Continuous (lifelong) ethical education of scientists and teachers
3-5 3Rs and training skills Theme
4: Knowledge Management and Information Services
Organizers
Carol Howard, CAAT, USA
Mary W. Wood, UC Davis, USA
Isao Yoshimura, Tokyo Univ. Science, Japan
4-1 Updates in 3Rs information and services
4-2 New developments in web retrieval technology
4-3 Regulatory requirements for the consideration of alternatives
4-4 Methodology for validation process of alternative assays
Theme 5: Toxicology/Validation
Organizers
Odile de Silva, L'Oreal, France
Julia Fentem, Unilever, UK
Leonard M. Schechtmann, FDA, USA
William S. Stokes, NICEATM, NIEHS, NIH, USA
Takashi Unno, JST, Organon Co. Ltd., Japan
Noriho Tanaka, FDSC, Japan
Hiroshi Itagaki, Shiseido Co. Ltd., Japan
5-1 Systemic toxicity
5-2 Local toxicity
5-3 Carcinogenicity
5-4 Genotoxicology (supported by JEMS)
5-5 Developmental and reproductive toxicity
5-6 Immunotoxicity
5-7 Neurotoxicity
5-8 Hepatotoxicity
5-9 in silico/(Q)SAR
5-10 Toxicokinetics
5-11 Validation
5-12 Others
Theme 6: Ecotoxicology
Organizers
Dr. Norihira Tatarazako, NIES, Japan
Shinobu Wakuri, FDSC, Japan with support from Tom Hutchinson, AstraZeneca, UK
6-1 Alternatives in ecotoxicology - the growing role of QSARs.
6-2 Use of invertebrates as alternatives for aquatic and terrestrial ecotoxicology.
6-3 Use of fi sh in regulatory ecotoxicology - progressing the 3Rs.
Theme 7: The 3Rs in the Development, Production and Quality Control of Biologicals
Organizers
Coenraad F. M. Hendricksen, Utrechit Univ, Netherlands
Richard Mcfarland, FDA, USA
Toru Kawanishi, NIHS, Japan
7-1 The consistency approach in vaccine quality control
7-2 3Rs Developments in safety testing of vaccines
7-3 In vitro quality control of rDNA protein drugs
7-4 Testing strategies for cell and gene therapies
7-5 Invalidation of specifi c quality control tests
7-6 Harmonization of guidelines and mutual recognition agreement
7-7 The contribution of regulatory bodies, pharmacopeias and validation bodies (Supported by ECVAM, ICCVAM)
7-8 Innovative technologies, such as omics and transgenic animals
Theme 8: Applying New Science and Technology from Basic Research for the 3Rs
Organizers
James Fuscoe, NCTR, FDA, USA
Vera Rogiers, Vrije Univ. Brussel, Belgium
Robert J. Kavlock, NCCT, US-EPA, USA
Takahiko Suzuki, JTCA, Univ. Tokyo, Japan
Yasuyuki Sakai, Univ. Tokyo, Japan
8-1 Stem cell science for potential applications in bioassays (Supported by JTCA)
8-2 Human cell usage
8-3 Tissue models
8-4 Imaging technology
8-5 Impacts of Nano-technology
8-6 New testing systems and high through-put screening
8-7 Omics' technologies, informatics and systems toxicology
8-8 Others
Theme 9: Globalization of 3Rs
Organizers
Jon Richmond, Home Offi ce, UK
Andrew N. Rowan, ACT, USA
Hajime Kojima, JaCVAM, NIHS, Japan
9-1 Globalization - Biologicals in developing countries
9-2 Globalization - Attitudes to severity assessment
9-3 Globalization - Validation & International cooperation
9-4 Globalization - One world or many worlds?
9-5 Globalization - Asian issues and perspectives
Theme 10: Risk Assessment Approach and Regulation
Organizers
Herman Koëter, EFSA, Italy
Manfred Liebsch, ZEBET, Germany
Christopher Portier, NIEHS, NIH, USA
Tsutomu M. Kurosawa, Osaka Univ., Japan
10-1 Risk assessment options based on redefi nement of objectives
10-2 Risk assessment strategies: new concepts and developments
10-3 Assessment of animal health risks and animal welfare risks
10-4 Humane endpoints: progress and regulatory acceptance
10-5 Linking risk assessment and risk management
Other scientific activities
1. Small group discussion
2. Round table discussion
3. Point-counterpoint sessions during lunch
4. Luncheon seminars supported by sponsors
5. Multimedia room
• The current scientific program as described above may be changed according to the abstract submission or other situations.